Work

REVEL : étude randomisée de phase III, en double insu, évaluant l’association docétaxel (D)-ramucirumab (R) versus D plus placebo (P) en deuxième ligne de traitement du CBNPC de stade IV

Year: 2014

Type: article

Study design: Clinical Trial

Source: Revue des Maladies Respiratoires

DOI: 10.1016/j.rmr.2014.10.066

Authors: D. Moro-Sibilot, A. Scherpereel, B. Mennecier, J. Otto, J. Mazières, C. Clement-Duchene, S. Yurasov, A. Zimmermann, G. Cuyun Carter, E.-B. Garon, M. Pérol

Institutions: Centre Hospitalier Universitaire de Grenoble, Hôpital Albert Calmette, Hôpitaux Universitaires de Strasbourg, Centre Antoine Lacassagne, Hôpital Rangueil, Eli Lilly (United States), University of California, Los Angeles, Centre Léon Bérard

Language: French

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2335683154

FWCI:

Cites:

Cited by:

Related to: 10